Novel Delivery Strategies for Oligos and Peptides - $600 Savings End Friday, 1/29

Register by this Friday, January 29th and receive up to a $600 savings – Use the code B16180BLOG100 to save. Click here to register.

Recent advances in delivery strategies have paved the way for improved targeting, efficacy and patient usability for the oligonucleotide and peptide therapeutic industry. Ensure that your team is up-to-date on the latest drug delivery strategies for accelerated product development by attending IBC's 18th Annual TIDES meeting, held May 9-12, 2016 in Long Beach, California.

Register today to attend the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization.

Industry Experts Present Novel Delivery Strategies for Oligonucleotides and Peptides:


Centyrins as Targeting Agents for Next-Generation Modular Therapeutics
Vadim Dudkin, Ph.D., Scientific Director, Centyrex, Johnson & Johnson

The biophysical properties of Centyrins make them ideal as targeting agents for a variety of novel delivery technologies. Centyrex is exploiting this platform via novel therapeutic applications aimed at addressing outstanding challenges in...(continue reading)
________________________________________

Treatment Opportunities for Cystic Fibrosis Using Aerosolized Antisense Oligonucleotides
Shuling Guo, Ph.D., Director, Antisense Drug Discovery, Isis Pharmaceuticals

Cystic fibrosis (CF) is one of the most common life-threatening genetic diseases affecting ~30,000 people within US and ~70,000 worldwide. Lung disease is the major cause of morbidity and mortality in CF. Antisense oligonucleotides (ASOs) administered by aerosol delivery distribute broadly into...(continue reading)
________________________________________

ITCA 650 (Exenatide Delivered Continuously via a Matchstick-Size Subcutaneous Osmotic Mini-Pump) an Investigational Therapy for Type-II Diabetes
Scott Peterson, Ph.D., Executive Director, Corporate Development, Intarcia Therapeutics, Inc.

ITCA 650, an investigational therapy for T2DM currently in Phase 3 clinical trials, is an osmotic mini-pump that can subcutaneously deliver exenatide (a GLP-1 receptor agonist) for extended periods of time. This presentation will cover the technology behind...(continue reading)


For more session information, download the complete agenda.

Share this article with your social network, just click below to share now!

Share |